Cargando…
Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
Autores principales: | Saha, Dipongkor, Martuza, Robert L., Rabkin, Samuel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616196/ https://www.ncbi.nlm.nih.gov/pubmed/28966936 http://dx.doi.org/10.18632/oncoscience.359 |
Ejemplares similares
-
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020) -
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
por: Jahan, Nusrat, et al.
Publicado: (2021) -
Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019) -
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021) -
Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models
por: Passer, Brent J., et al.
Publicado: (2012)